Concentration-controlled everolimus versus MMF in De Novo heart transplant patients:: Incidence of CMV infection at 12 months post-transplant in a randomized trial

被引：1

作者：

Dengler, T. ^{[1
]}

Vigano, M. ^{[2
]}

Magelli, C. ^{[3
]}

Guillemain, R. ^{[4
]}

Varnous, S. ^{[5
]}

Gerosa, G. ^{[6
]}

Poncelet, A. ^{[7
]}

Vanhaecke, J. ^{[8
]}

Li, Y. ^{[9
]}

Gezahegen, Y. ^{[9
]}

机构：

[1] Heidelberg Univ, Heidelberg, Germany

[2] Univ Pavia, IRCCS, Policlin S Matteo, I-27100 Pavia, Italy

[3] Az Osp Bologna, Policlin S Orsola Malpighi, Bologna, Italy

[4] Europeen Georges Pompidou, Paris, France

[5] Hop La Pitie Salpetriere, Paris, France

[6] Univ Padua, Azienda Osped Padova, Padua, Italy

[7] Clin Univ St Luc, Brussels, Belgium

[8] Univ Hosp Gasthuisberg, Louvain, Belgium

[9] Novartis Pharma AG, Basel, Switzerland

来源：

JOURNAL OF HEART AND LUNG TRANSPLANTATION | 2008年 / 27卷 / 02期

关键词：

D O I：

10.1016/j.healun.2007.11.020

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：S65 / S66

页数：2

共 50 条

[41] INCIDENCE OF INTERSTITIAL LUNG DISEASE WITH EVEROLIMUS IN TWO LARGE, RANDOMIZED, MULTICENTER STUDIES IN DE NOVO HEART OR KIDNEY TRANSPLANT RECIPIENTS
Lopez, P.
Shand, N.
Tufa, M.
Cibrik, D.
Lehmkuhl, H.
TRANSPLANT INTERNATIONAL, 2011, 24 : 58 - 58
[42] Impact of dose reductions on efficacy outcome in heart transplant patients receiving enteric-coated mycophenolate sodium (EC-MPS) or mycophenolate mofetil (MMF) at 12 months post-transplant
Segovia, Javier
Gerosa, Gino
Almenar, Luis
Livi, Ugolino
Vigano, Mario
Arizon, Jose Maria
Yonan, Nizar
TRANSPLANT INTERNATIONAL, 2007, 20 : 6 - 6
[43] RANDOMIZED, MULTICENTER STUDY OF EVEROLIMUS WITH EARLY REDUCTION OR ELIMINATION OF TACROLIMUS IN 719 DE NOVO LIVER TRANSPLANT RECIPIENTS: RESULTS AT 12 MONTHS
Saliba, Faouzi
Duvoux, Christophe
Durand, Francois
Neau-Cransac, Martine
Hardwigsen, Jean
Pageaux, Georges
Boleslawski, Emmanuel
TRANSPLANT INTERNATIONAL, 2012, 25 : 39 - 39
[44] Everolimus with reduced-exposure cyclosporine in de novo heart transplant patients: 6-month results of a multicenter, randomized trial.
Zuckermann, A.
Wang, S. S.
Keogh, A.
Ross, H.
Frigerio, M.
Eisen, H.
Bara, C.
Laufer, G.
Cotrufo, M.
Lena, S.
Sips, C.
AMERICAN JOURNAL OF TRANSPLANTATION, 2007, 7 : 443 - 443
[45] Wound events in kidney transplant patients receiving de novo everolimus: a pooled analysis of three randomized controlled trials
Cooper, M.
Wiseman, A. C.
Zibari, G.
McCague, K.
Kim, Y.
Geissier, F.
Nashan, B.
CLINICAL TRANSPLANTATION, 2013, 27 (06) : E625 - E635
[46] Prospective Randomized OPEN Trial Designed to Reduce the Incidence of Cytomegalovirus (CMV) Infection in DE NOVO Kidney Transplant Recipients Two-Year Results.
Esmeraldo, R.
Oliveira, M.
Pinheiro, P.
Girao, C.
Freitas, T.
AMERICAN JOURNAL OF TRANSPLANTATION, 2016, 16 : 218 - 218
[47] Efficacy and Safety of Concentration Controlled Everolimus with Reduced Dose Cyclosporine in Japanese Adult De-Novo Renal Transplant Patients: 12 Month Results
Takahara, S.
Uchida, K.
Yoshimura, N.
Teraoka, S.
Kobayashi, E.
Teshima, R.
Cornu-Artis, C.
Takahashi, K.
AMERICAN JOURNAL OF TRANSPLANTATION, 2012, 12 : 300 - 300
[48] Early Conversion to Everolimus in De Novo Renal Transplant Recipients: Incidence of Viral Infections in the Randomized-Controlled ELEVATE Study.
Hirsch, H.
De Fijter, J.
van der Giet, M.
Zeier, M.
Pascual, J.
Avihingsanon, Y.
Lopez, P.
Aguilar-Sanchez, J.
Kochuparampil, J.
Wang, Z.
Holdaas, H.
Cruzado, J.
AMERICAN JOURNAL OF TRANSPLANTATION, 2016, 16 : 293 - 294
[49] 4-year incidence of mace and economic burden in de novo heart transplant patients: A comparison of everolimus and azathiorrine (AZA)
Eisen, H.
Starling, R.
Kobashigawa, J.
JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2006, 25 (02): : S59 - S59
[50] 4-Year incidence of mace and economic burden in de novo heart transplant patients: A comparison of everolimus and azathioprine.
Eisen, H
Starling, R
Yang, XL
Ricci, JF
Kobashigawa, J
AMERICAN JOURNAL OF TRANSPLANTATION, 2005, 5 : 251 - 251

← 1 2 3 4 5 →